NAGOMI COMPLEX: Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

Sponsor

Terumo Europe N.V. (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05705973

Collaborator

(none)

3,000

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The NAGOMI COMPLEX PMCF (Post-Market Clinical Follow-up) study has been designed to expand the knowledge about outcomes with the Ultimaster Nagomi™ sirolimus eluting coronary stent system (Ultimaster Nagomi™) in complex PCI subjects. The features for a complex PCI are based upon subgroup analysis of earlier published studies.

Condition or Disease	Intervention/Treatment	Phase
Cardiovascular Disease Coronary Artery Occlusion Ischemic Heart Disease	Device: Ultimaster Nagomi™

Detailed Description

The study is a prospective, multi-center, post-market, non-interventional, observational, single-arm study. Subjects with an indication for a PCI according to current European Society of Cardiology (ESC) or national guidelines will be treated with the Ultimaster Nagomi™ in accordance with the intended use. The PCI procedure will be per hospital routine including the option, as per physician preference, to assess the functional severity of the lesion, perform intra-coronary imaging, use lesion preparation devices or to perform a staged procedure. Also, post-procedural anti-platelet medication will be per ESC or national guidelines.

The primary endpoint is Target Lesion Failure (TLF) defined as Cardiovascular Death (CD), Target-Vessel related Myocardial Infarction (TV-MI) and Clinically Driven Target Lesion Revascularization (CD-TLR) at 1 year. Secondary endpoints are a broad set of clinical endpoints defined by the Academic Research Consortium-II to fully characterize the performance of the Ultimaster Nagomi™ stent. Clinical events will be adjudicated by an independent Clinical Events Committee (CEC) to ensure a consistent assessment versus the event definitions. The Data Monitoring Committee (DMC) will simultaneously conduct regular review for accumulating data to ensure proper safety data monitoring. Core lab analysis of the baseline angiograms of bifurcation lesions by Quantitative Coronary Angiography (QCA) will be included. Procedural resource data will be collected for health-economic analysis. Subject reported outcomes will be documented using the EQ-5D-5L questionnaire and the Seattle Angina Questionnaire (SAQ) for the assessment of the quality of life and angina status, respectively.

The study will enroll 3,000 patients from European sites. Follow-up will be 2 years, except for subjects in whom no Ultimaster Nagomi™ stent was implanted and subjects that do not meet the inclusion criteria for a complex PCI as ascertained after the index procedure. These subjects will be followed until discharge.

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

3000 participants

Observational Model:

Other

Time Perspective:

Prospective

Official Title:

A Post-Market Clinical Follow-up Study With Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Subjects

Anticipated Study Start Date :

Mar 1, 2023

Anticipated Primary Completion Date :

Sep 1, 2026

Anticipated Study Completion Date :

Sep 1, 2027

Outcome Measures

Primary Outcome Measures

Target Lesion Failure (TLF) [at 1-year post procedure]
Defined as the composite of cardiovascular death, target-vessel related myocardial infarction and clinically driven target lesion revascularization.

Secondary Outcome Measures

Delivery success [Intraoperative]
Delivery success is defined as an achievement of successful delivery of study stent to the target lesion, expansion of the study stent and withdrawal of the delivery catheter.
Lesion success [Intraoperative]
Lesion success is defined as the attainment of < 30% residual stenosis by visual estimate and/or < 50% (by QCA) using any percutaneous method (if QCA was not available, the visual estimate of diameter stenosis is used).
Device success [Intraoperative]
Device Success is defined as delivery success with the achievement of a final residual diameter stenosis of the target lesion of < 30% by visual assessment and/or < 50% by QCA, using the assigned device only.
Procedure success [during hospitalization, approximately 3 days]
Procedure Success is defined as the achievement of < 30% residual stenosis by visual assessment in all target lesions using any percutaneous method without the occurrence of death, Q wave or WHO defined non-Q wave, or repeat revascularization of the target lesion during the hospital stay.
Target lesion failure (TLF) [at index procedure, 30 days, 6 months, 1 year, and 2 years]
The composite of cardiovascular death, MI (not clearly attributable to a nontarget vessel) and clinically driven Target lesion revascularization (TLR).
Patient oriented composite endpoint (POCE) [at index procedure, 30 days, 6 months, 1 year, and 2 years]
Defined as composite of all-cause mortality, any MI and any coronary revascularization.
Death and subclassifications [at index procedure, 30 days, 6 months, 1 year, and 2 years]
Death may be subclassified as: Cardiovascular death, Noncardiovascular death or Undetermined death. Cardiovascular death may include death caused by acute MI, death caused by sudden cardiac death, including unwitnessed, death resulting from heart failure, death caused by stroke, death caused by cardiovascular procedures, death resulting from cardiovascular hemorrhage, death resulting from other cardiovascular cause. Noncardiovascular death may include death from malignancy, death resulting from pulmonary causes, death caused by infection (including sepsis), death resulting from gastrointestinal causes, death resulting from accident/trauma, death caused by other noncardiovascular organ failure, death resulting from other. Undetermined cause of death is defined as a death not attributable to any other category because of the absence of any relevant source documents.
Myocardial infarction and subclassifications [at index procedure, 30 days, 6 months, 1 year, and 2 years]
Myocardial infarction - Absolute rise in cardiac troponin (from baseline) ≥35 times upper reference limit, plus 1 (or more) of the following criteria: New significant* Q waves or equivalent Flow-limiting angiographic complications New "substantial" loss of myocardium on imaging * Q-wave criteria requires the development of new Q waves ≥40 ms in duration and ≥1 mm deep in voltage in ≥2 contiguous leads.
Revascularization and subclassifications [at index procedure, 30 days, 6 months, 1 year, and 2 years]
Successful revascularization of all lesions with angiographically a diameter stenosis ≥ 50%
Stent thrombosis (ST) and subclassifications [at index procedure, 30 days, 6 months, 1 year, and 2 years]
Definite ST Presence of a thrombus that originates in the stent/scaffold or in the segment 5mm prox. or dist. to the stent/scaffold or in a side branch originating from the stented/scaffolded segment & at least 1 of the ff: Acute onset of ischemic symptoms at rest New ECG changes suggestive of acute ischemia Typical rise and fall in cardiac biomarkers Or Pathological confirmation of thrombosis Evidence of recent thrombus within the stent/scaffold determined at autopsy Examination of tissue retrieved ff. thrombectomy Probable ST Any MI that is related to documented acute ischemia in the territory of the implanted stent/scaffold w/out angiographic confirmation of stent/scaffold thrombosis and in the absence of any other obvious cause. Occlusive thrombus Thrombolysis in MI grade 0/1 flow w/in or prox. to a stent/scaffold segment. Nonocclusive thrombus Intracoronary thrombus defined as a noncalcified filling defect or lucency surrounded by contrast material seen in mu
Bleeding (Bleeding Academic Research Consortium (BARC) 3-5) [at index procedure, 30 days, 6 months, 1 year, and 2 years]
Type 3:Clinical, lab, and/or imaging evidence of bleeding w/ specific healthcare provider responses, as below: Type 3a Any BT with overt bleeding Overt bleeding plus Hgb drop ≥3 to < 5 g/dL Type 3b Overt bleeding plus Hgb drop ≥5 g/dL Cardiac tamponade Bleeding requiring surgical intervention for control Bleeding requiring IV vasoactive drugs Type 3c Intracranial hemorrhage Type 4:CABG-related bleeding Perioperative intracranial bleeding w/in 48 hr Reoperation after closure of sternotomy for bleeding control Transfusion of ≥5 U whole blood or packed RBC w/in a 48-hr period Chest tube output ≥2 L w/in a 24-hr period Type 5:Fatal bleeding Bleeding that directly causes death with no other explainable cause. Categorized as: Type 5a Probable bleeding that is clinically suspicious as the cause of death, but bleeding is not directly observed and no autopsy or confirmatory imaging. Type 5b Definite bleeding that is directly observed (clinical specimen or imaging)
Balance between bleeding (BARC 3-5) and thrombotic event (myocardial infarction and/or stent thrombosis) [at index procedure, 30 days, 6 months, 1 year, and 2 years]
Utilization of cardiovascular health care resources [at index procedure, 30 days, 6 months, 1 year, and 2 years]
Quality of Life assessment [at baseline, 30 days, 6 months, 1 year, and 2 years]
Quality of Life assessed as per EuroQl five-dimensional (EQ-5D) questionnaire: The first part of the questionnaire contain descriptive questions on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, each with 5 levels of responses. The second part of the questionnaire contains a standard vertical 20-cm visual analog scale that is calibrated from 'the worst health you can imagine' (scored 0) at its base to 'the best health you can imagine' (scored 100) at its apex.
Angina status assessment Seattle Angina Questionnaire (SAQ) [at baseline, 30 days, 6 months, 1 year, and 2 years]
Angina status will be assessed through the Seattle Angina Questionnaire (SAQ). The SAQ is a validated disease-specific instrument for assessing the health status of patients with coronary artery disease
QCA of the index procedure angiogram for a subset of patients with a Complex Bifurcation Lesion (CBL) [procedure]
Luminal dimensions of bifurcation lesions will be measured by off-line quantitative coronary angiography by a central core laboratory. The objective of the QCA is to quantitate and express the benefit of the Proximal Optimisation Technique (POT). The POT balloon positioning is of importance in this technique as well as the balloon diameter to obtain optimal stent apposition in the main branch.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

General Inclusion Criteria:

Age ≥ 18 years
Patient has been informed of the nature of the study and agrees to its provisions, has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site
Ischemic heart disease with an indication for a PCI with, if available and per hospital guidelines, Heart Team consensus for a PCI procedure
Intention to treat all lesions requiring a PCI with the Ultimaster Nagomi stent

Complex Procedure Inclusion Criteria

Subject meets ≥ 1 of the complex procedure criteria:

Multivessel disease defined as ≥ 2 native coronary arteries and/or venous or arterial bypass grafts with a lesion requiring PCI
≥ 3 stents implanted
≥ 3 lesions treated
Complex bifurcation lesion defined as true bifurcation lesion (Medina 1.1.1, 1.0.1 or 0.1.1) with a side branch diameter > 2.5 mm plus one of the following:

side branch disease > 10 mm ii) calcified lesion iii) thrombotic lesion e) Bifurcation lesion implanted with two stents f) Total stent length implanted > 60 mm g) Chronic total occlusion defined as a 100% occlusion with antegrade TIMI 0 flow with at least a 3-month duration h) Left main stenting (main stem and/or bifurcation) i) Instent restenosis j) Severe calcified lesion with use of atherectomy or lithotripsy

Exclusion Criteria:

Any surgery requiring general anaesthesia, comorbidity or indication likely necessitating the discontinuation of dual anti-platelet therapy before the recommended duration of dual anti-platelet therapy per the ESC or national guidelines
An acute or evolving STEMI < 72 h after symptom onset
Hypersensitivity or contraindication to aspirin, heparin, L605 cobalt-chromium alloy, sirolimus or its structurally related compounds, lactide polymers or caprolactone polymers that cannot be pre-medicated
Known contrast sensitivity that cannot be premedicated
Pregnant and breastfeeding women
Life expectancy < 1 year for any cardiac or non-cardiac cause
Participation in another clinical study that has not yet completed its primary endpoint
Earlier enrolment in the Nagomi Complex study
Unlikely to be available for follow-up during the duration of the study (2 years)